Table: q1_q4_2020_prescription_drugs_wac_increases , manufacturer_name like F*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000063	Ferring Pharmaceuticals	06/30/2020	55566280001	Cervidil 10MG VAGINAL INSERT (dinoprostone, 10mg)	04/28/2020	24.64	435.23	None	Single Source Drug	None	1	None	1	None	1	10/01/2015	Allergan plc	None	1	None	306.27	None	1995	140.00	None	None
Rx0000063	Ferring Pharmaceuticals	03/31/2020	55566750102	MENOPUR (menotropins for injection)/75 units/vial - 5 single-dose vials per package	02/20/2020	59.30	1047.55	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Note: The acquisition fields do not apply because Ferring did not acquire the product within the past five years. NDC 55566750101 is the NDC for the 0.9% Sodium Chloride Injection, USP, 2 mL product included in the Menopur kit. The Sodium Chloride is used for mixing the medicine. NDC 55566750101 does not have a WAC price. "
Rx0000193	Forte Bio-Pharma, LLC	12/31/2020	72245019310	Nalocet 2.5mg/300mg Tablet 100Ct	10/01/2020	218.50	2403.50	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000193	Forte Bio-Pharma, LLC	12/31/2020	72245019303	Nalocet 2.5mg/300mg Tablet 30ct	10/01/2020	65.55	721.05	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2020	63323016505	Dexamethasone Sodium Phosphate Liquid 20 mg 5mL	03/21/2020	13.75	157.75	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=335	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Fresenius Kabi USA (“Fresenius Kabi”) believes is otherwise in the public domain or publicly available. Where possible, Fresenius Kabi has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column F, Fresenius Kabi did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns N-U, Fresenius Kabi has not provided a response for "drug products" (as defined in the regulations) that were not acquired in their finished form from an unrelated company in the previous 5 years. (4) Fresenius Kabi USA's product portfolio, including this product, consists primarily of sterile injectable products administered during a patient's inpatient hospital stay. Such hospital stays are subject to variability depending upon a particular patient's needs. The dosing requirements as set forth in the prescribing information for these products are given as a range, based in large part on the number of days of the patient's admission. As such, Fresenius Kabi has based its calculations for purposes of this submission on the recommended dosage for the average length of stay within range present in the product's prescribing information. For example, if a product's prescribing information requires the administration of 1 vial of drug product per day over the course of a 3 to 5 day admission, Fresenius Kabi has based the calculation on 1 vial administered during a 4-day patient admission (an average of the 3-5 day range).
Rx0000129	Fresenius Kabi USA LLC	09/30/2020	63323022935	Protamine Sulfate Inj. 250mg 25mL SDV NOVAPLUS	07/01/2020	3.05	29.17	None	Non-innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Drug was not acquired within the previous 5 years
Rx0000129	Fresenius Kabi USA LLC	09/30/2020	63323022915	Protamine Sulfate Inj. 50mg 5mL SDV NOVAPLUS	07/01/2020	27.50	244.75	None	Non-innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Drug was not acquired within the previous 5 years